JP2012504605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504605A5 JP2012504605A5 JP2011530049A JP2011530049A JP2012504605A5 JP 2012504605 A5 JP2012504605 A5 JP 2012504605A5 JP 2011530049 A JP2011530049 A JP 2011530049A JP 2011530049 A JP2011530049 A JP 2011530049A JP 2012504605 A5 JP2012504605 A5 JP 2012504605A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyridin
- heteroaryl
- methyl
- cor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000005843 halogen group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- -1 [1,2,3] -oxadiazolyl Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 1
- QTJAJWGUOFANQB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(pyridin-2-ylamino)phenyl]phenyl]benzamide Chemical compound C1=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)C(C)=CC=C1NC1=CC=CC=N1 QTJAJWGUOFANQB-UHFFFAOYSA-N 0.000 claims 1
- SPGLFSJXXQQQDC-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-(imidazol-1-ylmethyl)-2-methylphenyl]phenyl]benzamide Chemical compound C1=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)C(C)=CC=C1CN1C=CN=C1 SPGLFSJXXQQQDC-UHFFFAOYSA-N 0.000 claims 1
- AEENUTOHWJNIGF-UHFFFAOYSA-N 3-fluoro-n-[5-(2-methoxy-5-pyridin-2-yloxyphenyl)pyridin-2-yl]-2-methylbenzamide Chemical compound C1=C(C=2C=NC(NC(=O)C=3C(=C(F)C=CC=3)C)=CC=2)C(OC)=CC=C1OC1=CC=CC=N1 AEENUTOHWJNIGF-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- HIJDPDIYOMOGNP-UHFFFAOYSA-N n-[4-(2-chloro-5-pyridin-2-yloxyphenyl)phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3N=CC=CC=3)C=2)Cl)C=C1 HIJDPDIYOMOGNP-UHFFFAOYSA-N 0.000 claims 1
- LWOAQWOBNADBCW-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yloxy)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3SC=CN=3)C=2)Cl)C=C1 LWOAQWOBNADBCW-UHFFFAOYSA-N 0.000 claims 1
- QZFKZBDVJMCFTO-UHFFFAOYSA-N n-[4-[2-chloro-5-[(5-methyl-1,3-thiazol-2-yl)oxy]phenyl]phenyl]-2,6-difluorobenzamide Chemical compound S1C(C)=CN=C1OC1=CC=C(Cl)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 QZFKZBDVJMCFTO-UHFFFAOYSA-N 0.000 claims 1
- NHCDCWOPKPVLCP-UHFFFAOYSA-N n-[5-(2-chloro-5-pyridin-2-yloxyphenyl)pyrazin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CN=C(C=2C(=CC=C(OC=3N=CC=CC=3)C=2)Cl)C=N1 NHCDCWOPKPVLCP-UHFFFAOYSA-N 0.000 claims 1
- UOOBTQFJZJTPBJ-UHFFFAOYSA-N n-[5-(2-chloro-5-pyridin-2-yloxyphenyl)pyridin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3N=CC=CC=3)C=2)Cl)C=N1 UOOBTQFJZJTPBJ-UHFFFAOYSA-N 0.000 claims 1
- CYMYUDMSWBMQQB-UHFFFAOYSA-N n-[5-[2-chloro-5-(1,3-thiazol-2-yloxy)phenyl]pyridin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(OC=3SC=CN=3)C=2)Cl)C=N1 CYMYUDMSWBMQQB-UHFFFAOYSA-N 0.000 claims 1
- SIBCEONRAQUSQQ-UHFFFAOYSA-N n-[5-[2-chloro-5-[5-(3-methylimidazol-4-yl)-1,3-thiazol-2-yl]phenyl]pyridin-2-yl]-2,6-difluorobenzamide Chemical compound CN1C=NC=C1C1=CN=C(C=2C=C(C(Cl)=CC=2)C=2C=NC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)S1 SIBCEONRAQUSQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19483008P | 2008-10-01 | 2008-10-01 | |
| US61/194,830 | 2008-10-01 | ||
| PCT/US2009/005408 WO2010039238A1 (en) | 2008-10-01 | 2009-10-01 | Compounds for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504605A JP2012504605A (ja) | 2012-02-23 |
| JP2012504605A5 true JP2012504605A5 (enExample) | 2012-11-15 |
Family
ID=41366981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530049A Pending JP2012504605A (ja) | 2008-10-01 | 2009-10-01 | 炎症および免疫関連使用のための化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20100130522A1 (enExample) |
| EP (1) | EP2350006A1 (enExample) |
| JP (1) | JP2012504605A (enExample) |
| AU (1) | AU2009300318A1 (enExample) |
| CA (1) | CA2739303A1 (enExample) |
| TW (1) | TW201018667A (enExample) |
| WO (1) | WO2010039238A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085581A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| WO2010085584A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| HUE029570T2 (en) | 2010-04-27 | 2017-03-28 | Calcimedica Inc | Intracellular calcium modifying compounds |
| CN103180316A (zh) | 2010-08-27 | 2013-06-26 | 钙医学公司 | 调节细胞内钙的化合物 |
| PL2632906T3 (pl) * | 2010-10-30 | 2016-09-30 | Oksazolinowe i izoksazolinowe pochodne jako modulatory kanałów typu CRAC | |
| WO2012112670A1 (en) * | 2011-02-16 | 2012-08-23 | Albert Einstein College Of Medicine Of Yeshiva University | Novel lipogenic inhibitors and uses thereof |
| EP2704701B1 (en) | 2011-05-03 | 2018-01-03 | PRCL Research Inc. | Compounds for inflammation and immune-related uses |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP2014532656A (ja) * | 2011-10-28 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のための化合物 |
| US9399638B2 (en) | 2012-05-02 | 2016-07-26 | Lupin Limited | Substituted pyridine compounds as CRAC modulators |
| CA2871222A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyrazole compounds as crac modulators |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| US9725463B2 (en) | 2013-06-21 | 2017-08-08 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| US9790231B2 (en) | 2013-06-24 | 2017-10-17 | Lupin Limited | Chromane and chromene derivatives and their use as CRAC modulators |
| EP3066072B1 (en) * | 2013-11-07 | 2021-11-03 | The University of Kansas | Biphenylamide derivative hsp90 inhibitors |
| WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| CN114712513B (zh) | 2015-02-27 | 2026-02-10 | 钙医学公司 | 胰腺炎治疗 |
| CA2994404C (en) | 2015-08-03 | 2020-12-08 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof |
| AU2016306301B2 (en) | 2015-08-07 | 2021-02-11 | Calcimedica, Inc. | Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| CN113557020A (zh) | 2018-09-14 | 2021-10-26 | 瑞真药业公司 | 包含crac抑制剂和皮质类固醇的组合物及其使用方法 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN111662227B (zh) * | 2019-03-06 | 2022-07-05 | 中国科学院上海药物研究所 | 邻氨基吡啶炔类化合物及其制备方法和用途 |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| US12544371B2 (en) | 2020-03-20 | 2026-02-10 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
| US12522589B2 (en) | 2020-11-13 | 2026-01-13 | Calcimedica, Inc. | Synthesis of CRAC channel inhibitors |
| CN118084860A (zh) * | 2024-02-06 | 2024-05-28 | 中国药科大学 | 芳酰胺类化合物及其药物组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2140354B1 (es) * | 1998-08-03 | 2000-11-01 | S A L V A T Lab Sa | Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2. |
| US6353007B1 (en) * | 2000-07-13 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| CA2495437A1 (en) * | 2002-08-27 | 2004-03-11 | Yamanouchi Pharmaceutical Co., Ltd. | Novel crystal |
| MX2007008290A (es) * | 2005-01-07 | 2008-02-15 | Synta Pharmaceuticals Corp | Compuestos para inflamacion y usos inmuno-relacionados. |
| US8518950B2 (en) * | 2005-01-25 | 2013-08-27 | Synta Pharmaceuticals Corp. | 2-amido pyrazines for inflammation and immune related uses |
| DK1984338T3 (da) * | 2006-01-31 | 2013-04-22 | Synta Pharmaceuticals Corp | Pyridylphenylforbindelser til inflammations- og immunrelaterede anvendelser |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
-
2009
- 2009-10-01 CA CA2739303A patent/CA2739303A1/en not_active Abandoned
- 2009-10-01 US US12/572,088 patent/US20100130522A1/en not_active Abandoned
- 2009-10-01 JP JP2011530049A patent/JP2012504605A/ja active Pending
- 2009-10-01 AU AU2009300318A patent/AU2009300318A1/en not_active Abandoned
- 2009-10-01 EP EP09789389A patent/EP2350006A1/en not_active Withdrawn
- 2009-10-01 TW TW098133368A patent/TW201018667A/zh unknown
- 2009-10-01 WO PCT/US2009/005408 patent/WO2010039238A1/en not_active Ceased
-
2012
- 2012-01-25 US US13/358,020 patent/US20120196838A1/en not_active Abandoned
-
2013
- 2013-10-15 US US14/054,610 patent/US20140045861A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509342A5 (enExample) | ||
| JP2010535218A5 (enExample) | ||
| JP2012504604A5 (enExample) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2010535214A5 (enExample) | ||
| JP2010535215A5 (enExample) | ||
| JP2017501234A5 (enExample) | ||
| JP2021504443A5 (enExample) | ||
| JP2008513508A5 (enExample) | ||
| HRP20231389T1 (hr) | Spojevi piridazinona i njihove upotrebe | |
| JP2004521095A5 (enExample) | ||
| RU2007124935A (ru) | АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ | |
| JP2013531055A5 (enExample) | ||
| EP1157022A1 (en) | Pyridine compounds and their pharmaceutical use | |
| WO2011042797A4 (en) | Pyrazole derivatives as modulators of calcium release -activated calcium channel | |
| JP2008050365A5 (enExample) | ||
| WO2010039238A1 (en) | Compounds for inflammation and immune-related uses | |
| JP2013505969A5 (enExample) | ||
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| JP2009531309A5 (enExample) | ||
| KR20140009374A (ko) | Ｐ2ｘ7 수용체 안타고니스트로서의 벤즈아미드 유도체 | |
| EP1442024A1 (en) | AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS | |
| JP2016512515A5 (enExample) | ||
| JP2019535788A5 (enExample) | ||
| US20120053170A1 (en) | Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs |